p.P476S mutation of RBPJL inhibits the efficacy of anti‐PD‐1 therapy in oesophageal squamous cell carcinoma by blunting T‐cell responses

OBJECTIVES: Anti‐PD‐1 immune checkpoint blockade represents the onset of a new era in cancer immunotherapy. However, robust predictors are necessary for screening patients with immune checkpoint‐responsive oesophageal squamous cell carcinoma (ESCC). METHODS: We obtained biopsy samples from an ESCC p...

Descripción completa

Detalles Bibliográficos
Autores principales: Miao, Lei, Wei, Xiao‐Li, Zhao, Qi, Qi, JingJing, Ren, Chao, Wu, Qi‐Nian, Wei, Da‐Liang, Liu, Jia, Wang, Feng‐Hua, Xu, Rui‐Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7507108/
https://www.ncbi.nlm.nih.gov/pubmed/32994998
http://dx.doi.org/10.1002/cti2.1172

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7507108/
https://www.ncbi.nlm.nih.gov/pubmed/32994998
http://dx.doi.org/10.1002/cti2.1172

Ejemplares similares